Science

Thought Leadership

Providing Thought Leadership is our commitment to improving the science of laboratory testing for the insurance industry. Providing our clients a competitive advantage is our unwavering commitment. As Thought Leaders, we drive perpetual discovery to inspire change. We will continue to be at the forefront of questioning the status quo, while applying valid science and research analysis to improve risk selection—that's the result of Thought Leadership.

CRL's published Research & Development:

HbA1c values from 5 to 7% and mortality*

HbA1c more lives with added detail

Albumin and all-cause mortality*

Serum alcohol and CDT (heavy use marker) and mortality*

Bilirubin levels and mortality*

CEA screening of "healthy" adults and mortality*

CEA with more lives and detail

Lipid tests and ratios as mortality predictors*

Cocaine the real risk

Smoking (urine cotinine levels) and mortality risk

Glucosuria and mortality risk

Liver enzymes in a very large "healthy" cohort (ALT, AST, GGT & AP) and mortality*

Non-cig tobacco use and mortality

*-peer reviewed medical journal article

Robert L. Stout, Ph.D.

President

Dr. Stout has been with CRL since 1983 and is responsible for day to day directorship of CRL's college of American Pathologists (CAP)-Accredited reference laboratory.

Dr. Stout holds U.S. Patents in science, including one for immunoassay method and apparatus development and one for methods of determining chronic Hepatitis C infection. He is the author of numerous research and review articles and is a regular presenter at scientific meetings and conferences, recently presenting "Laboratory Tests: Clinical vs. Insurance Medicine" at ICLAM International Committee for Life, Disability & Health Assurance Medicine in Italy.

Dr. Stout holds a B.S. in Biochemistry from California State University and a Ph.D. in Biological Chemistry from U.C.L.A. School of Medicine.

Patents

1. Treatment of Mammals with Natural Killer Activating Factor

2. Catalyzed Colorimetric and Fluorometric Substrates for

Peroxidase Enzyme Determinations

3. Biologic and Method of Preparing the Same

4. Immunoassay Method and Apparatus

5. Method for the Determination of Antigens and Antibodies Using

Site-Deactivating Media

6. Method of Increasing Natural Killer Cell Population of Cancer

Patients

7. Capillary Electrophoresis of Transferrin Glycoforms

8. Hepatitis C Screening Assay and Methods of Use Thereof

9. Methods for Assessment of Cardiovascular Disease Risk

Michael W. Fulks, MD

Consulting Medical Director

Dr. Fulks in an internist with both practice and insurance medicine experience including translation of medical research into underwriting standards who joined the research team in 2006.

Vera F. Dolan, MSPH

Clinical Reference Laboratory

Senior Research Scientist

Ms. Dolan has added her epidemiology background and her insurance research and writing skills to the team since 2005.